{"id":787534,"date":"2023-10-02T18:58:49","date_gmt":"2023-10-02T22:58:49","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-host-investor-call-and-webcast-on-october-3-2023-to-share-interim-phase-2-aspen-06-clinical-trial-results-of-evorpacept-for-the-treatment-of-advanced-her2-positive-gastric-cancer\/"},"modified":"2023-10-02T18:58:49","modified_gmt":"2023-10-02T22:58:49","slug":"alx-oncology-to-host-investor-call-and-webcast-on-october-3-2023-to-share-interim-phase-2-aspen-06-clinical-trial-results-of-evorpacept-for-the-treatment-of-advanced-her2-positive-gastric-cancer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-host-investor-call-and-webcast-on-october-3-2023-to-share-interim-phase-2-aspen-06-clinical-trial-results-of-evorpacept-for-the-treatment-of-advanced-her2-positive-gastric-cancer\/","title":{"rendered":"ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer"},"content":{"rendered":"
\n

SOUTH SAN FRANCISCO, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (\u201cALX Oncology\u201d or the \u201cCompany\u201d) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced the hosting of an investor call and webcast on Tuesday, October 3rd<\/sup> at 8:00 AM EDT to share interim Phase 2 ASPEN-06 clinical trial results of evorpacept for the treatment of advanced HER2-positive gastric cancer.<\/p>\n

To access the live conference call, please dial (800) 715-9871 (U.S.\/Canada) or +44.800.260.6466 (internationally), Conference ID 7797378. To access the live and archived webcast of the conference call, please visit the News & Events section (see \u201cEvents”)\u00a0of the Company\u2019s website at\u00a0www.alxoncology.com<\/a> where a slide presentation will be referenced during the event.<\/p>\n

\n About ALX Oncology<\/strong>\n <\/p>\n

ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 immune checkpoint inhibitor and bridge the innate and adaptive immune system. ALX Oncology\u2019s lead product candidate, evorpacept, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. Evorpacept has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer antibodies. ALX Oncology is currently focusing on combining evorpacept with anti-cancer antibodies, ADCs, and PD-1\/PD-L1 immune checkpoint inhibitors.<\/p>\n


\n
\n \n <\/div>\n

\n
Investor Contact:\r\nPeter Garcia\r\nChief Financial Officer, ALX Oncology\r\n(650) 466-7125 Ext. 113\r\npeter@alxoncology.com\r\n\r\nMalini Chatterjee, Ph.D.\r\nBlueprint Life Science Group\r\nmchatterjee@bplifescience.com\r\n\r\nMedia Contact:\r\nKaren Sharma\r\nMacDougall\r\n(781) 235-3060\r\nalx@macbiocom.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"
SOUTH SAN FRANCISCO, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (\u201cALX Oncology\u201d or the \u201cCompany\u201d) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced the hosting of an investor call and webcast on Tuesday, October 3rd at 8:00 AM EDT to share interim Phase 2 ASPEN-06 clinical trial results of evorpacept for the treatment of advanced HER2-positive gastric cancer. To access the live conference call, please dial (800) 715-9871 (U.S.\/Canada) or +44.800.260.6466 (internationally), Conference ID 7797378. To access the live and archived webcast of the conference call, please visit the News & Events section (see \u201cEvents”)\u00a0of the Company\u2019s website at\u00a0www.alxoncology.com where a slide presentation will be referenced during the … <\/p>\n
Continue reading “ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-787534","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-host-investor-call-and-webcast-on-october-3-2023-to-share-interim-phase-2-aspen-06-clinical-trial-results-of-evorpacept-for-the-treatment-of-advanced-her2-positive-gastric-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (\u201cALX Oncology\u201d or the \u201cCompany\u201d) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced the hosting of an investor call and webcast on Tuesday, October 3rd at 8:00 AM EDT to share interim Phase 2 ASPEN-06 clinical trial results of evorpacept for the treatment of advanced HER2-positive gastric cancer. To access the live conference call, please dial (800) 715-9871 (U.S.\/Canada) or +44.800.260.6466 (internationally), Conference ID 7797378. To access the live and archived webcast of the conference call, please visit the News & Events section (see \u201cEvents”)\u00a0of the Company\u2019s website at\u00a0www.alxoncology.com where a slide presentation will be referenced during the … Continue reading "ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-host-investor-call-and-webcast-on-october-3-2023-to-share-interim-phase-2-aspen-06-clinical-trial-results-of-evorpacept-for-the-treatment-of-advanced-her2-positive-gastric-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-02T22:58:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODk0MTYyMCM1ODUxNDIyIzIxOTI4NjM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-host-investor-call-and-webcast-on-october-3-2023-to-share-interim-phase-2-aspen-06-clinical-trial-results-of-evorpacept-for-the-treatment-of-advanced-her2-positive-gastric-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-host-investor-call-and-webcast-on-october-3-2023-to-share-interim-phase-2-aspen-06-clinical-trial-results-of-evorpacept-for-the-treatment-of-advanced-her2-positive-gastric-cancer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer\",\"datePublished\":\"2023-10-02T22:58:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-host-investor-call-and-webcast-on-october-3-2023-to-share-interim-phase-2-aspen-06-clinical-trial-results-of-evorpacept-for-the-treatment-of-advanced-her2-positive-gastric-cancer\\\/\"},\"wordCount\":255,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-host-investor-call-and-webcast-on-october-3-2023-to-share-interim-phase-2-aspen-06-clinical-trial-results-of-evorpacept-for-the-treatment-of-advanced-her2-positive-gastric-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODk0MTYyMCM1ODUxNDIyIzIxOTI4NjM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-host-investor-call-and-webcast-on-october-3-2023-to-share-interim-phase-2-aspen-06-clinical-trial-results-of-evorpacept-for-the-treatment-of-advanced-her2-positive-gastric-cancer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-host-investor-call-and-webcast-on-october-3-2023-to-share-interim-phase-2-aspen-06-clinical-trial-results-of-evorpacept-for-the-treatment-of-advanced-her2-positive-gastric-cancer\\\/\",\"name\":\"ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-host-investor-call-and-webcast-on-october-3-2023-to-share-interim-phase-2-aspen-06-clinical-trial-results-of-evorpacept-for-the-treatment-of-advanced-her2-positive-gastric-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-host-investor-call-and-webcast-on-october-3-2023-to-share-interim-phase-2-aspen-06-clinical-trial-results-of-evorpacept-for-the-treatment-of-advanced-her2-positive-gastric-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODk0MTYyMCM1ODUxNDIyIzIxOTI4NjM=\",\"datePublished\":\"2023-10-02T22:58:49+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-host-investor-call-and-webcast-on-october-3-2023-to-share-interim-phase-2-aspen-06-clinical-trial-results-of-evorpacept-for-the-treatment-of-advanced-her2-positive-gastric-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-host-investor-call-and-webcast-on-october-3-2023-to-share-interim-phase-2-aspen-06-clinical-trial-results-of-evorpacept-for-the-treatment-of-advanced-her2-positive-gastric-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-host-investor-call-and-webcast-on-october-3-2023-to-share-interim-phase-2-aspen-06-clinical-trial-results-of-evorpacept-for-the-treatment-of-advanced-her2-positive-gastric-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODk0MTYyMCM1ODUxNDIyIzIxOTI4NjM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODk0MTYyMCM1ODUxNDIyIzIxOTI4NjM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-host-investor-call-and-webcast-on-october-3-2023-to-share-interim-phase-2-aspen-06-clinical-trial-results-of-evorpacept-for-the-treatment-of-advanced-her2-positive-gastric-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-host-investor-call-and-webcast-on-october-3-2023-to-share-interim-phase-2-aspen-06-clinical-trial-results-of-evorpacept-for-the-treatment-of-advanced-her2-positive-gastric-cancer\/","og_locale":"en_US","og_type":"article","og_title":"ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer - Market Newsdesk","og_description":"SOUTH SAN FRANCISCO, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (\u201cALX Oncology\u201d or the \u201cCompany\u201d) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced the hosting of an investor call and webcast on Tuesday, October 3rd at 8:00 AM EDT to share interim Phase 2 ASPEN-06 clinical trial results of evorpacept for the treatment of advanced HER2-positive gastric cancer. To access the live conference call, please dial (800) 715-9871 (U.S.\/Canada) or +44.800.260.6466 (internationally), Conference ID 7797378. To access the live and archived webcast of the conference call, please visit the News & Events section (see \u201cEvents”)\u00a0of the Company\u2019s website at\u00a0www.alxoncology.com where a slide presentation will be referenced during the … Continue reading \"ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-host-investor-call-and-webcast-on-october-3-2023-to-share-interim-phase-2-aspen-06-clinical-trial-results-of-evorpacept-for-the-treatment-of-advanced-her2-positive-gastric-cancer\/","og_site_name":"Market Newsdesk","article_published_time":"2023-10-02T22:58:49+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODk0MTYyMCM1ODUxNDIyIzIxOTI4NjM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-host-investor-call-and-webcast-on-october-3-2023-to-share-interim-phase-2-aspen-06-clinical-trial-results-of-evorpacept-for-the-treatment-of-advanced-her2-positive-gastric-cancer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-host-investor-call-and-webcast-on-october-3-2023-to-share-interim-phase-2-aspen-06-clinical-trial-results-of-evorpacept-for-the-treatment-of-advanced-her2-positive-gastric-cancer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer","datePublished":"2023-10-02T22:58:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-host-investor-call-and-webcast-on-october-3-2023-to-share-interim-phase-2-aspen-06-clinical-trial-results-of-evorpacept-for-the-treatment-of-advanced-her2-positive-gastric-cancer\/"},"wordCount":255,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-host-investor-call-and-webcast-on-october-3-2023-to-share-interim-phase-2-aspen-06-clinical-trial-results-of-evorpacept-for-the-treatment-of-advanced-her2-positive-gastric-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODk0MTYyMCM1ODUxNDIyIzIxOTI4NjM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-host-investor-call-and-webcast-on-october-3-2023-to-share-interim-phase-2-aspen-06-clinical-trial-results-of-evorpacept-for-the-treatment-of-advanced-her2-positive-gastric-cancer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-host-investor-call-and-webcast-on-october-3-2023-to-share-interim-phase-2-aspen-06-clinical-trial-results-of-evorpacept-for-the-treatment-of-advanced-her2-positive-gastric-cancer\/","name":"ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-host-investor-call-and-webcast-on-october-3-2023-to-share-interim-phase-2-aspen-06-clinical-trial-results-of-evorpacept-for-the-treatment-of-advanced-her2-positive-gastric-cancer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-host-investor-call-and-webcast-on-october-3-2023-to-share-interim-phase-2-aspen-06-clinical-trial-results-of-evorpacept-for-the-treatment-of-advanced-her2-positive-gastric-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODk0MTYyMCM1ODUxNDIyIzIxOTI4NjM=","datePublished":"2023-10-02T22:58:49+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-host-investor-call-and-webcast-on-october-3-2023-to-share-interim-phase-2-aspen-06-clinical-trial-results-of-evorpacept-for-the-treatment-of-advanced-her2-positive-gastric-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-host-investor-call-and-webcast-on-october-3-2023-to-share-interim-phase-2-aspen-06-clinical-trial-results-of-evorpacept-for-the-treatment-of-advanced-her2-positive-gastric-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-host-investor-call-and-webcast-on-october-3-2023-to-share-interim-phase-2-aspen-06-clinical-trial-results-of-evorpacept-for-the-treatment-of-advanced-her2-positive-gastric-cancer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODk0MTYyMCM1ODUxNDIyIzIxOTI4NjM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODk0MTYyMCM1ODUxNDIyIzIxOTI4NjM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-host-investor-call-and-webcast-on-october-3-2023-to-share-interim-phase-2-aspen-06-clinical-trial-results-of-evorpacept-for-the-treatment-of-advanced-her2-positive-gastric-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/787534","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=787534"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/787534\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=787534"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=787534"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=787534"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}